Zenas BioPharma, Inc. (ZBIO)
29.43
+1.17
(+4.14%)
USD |
NASDAQ |
Nov 09, 14:29
Zenas BioPharma Price to Book Value : 9.398 for Nov. 9, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 9.024 |
| November 05, 2026 | 8.280 |
| November 04, 2026 | 9.088 |
| November 03, 2026 | 9.062 |
| November 02, 2026 | 8.820 |
| October 30, 2026 | 9.066 |
| October 29, 2026 | 9.184 |
| October 28, 2026 | 9.187 |
| October 27, 2026 | 8.718 |
| October 26, 2026 | 8.698 |
| October 23, 2026 | 8.580 |
| October 22, 2026 | 9.014 |
| October 21, 2026 | 8.967 |
| October 20, 2026 | 8.999 |
| October 19, 2026 | 8.529 |
| October 16, 2026 | 7.932 |
| October 15, 2026 | 8.111 |
| October 14, 2026 | 7.938 |
| October 13, 2026 | 8.034 |
| October 12, 2026 | 8.430 |
| October 09, 2026 | 8.705 |
| October 08, 2026 | 8.379 |
| October 07, 2026 | 8.999 |
| October 06, 2026 | 8.603 |
| October 05, 2026 | 8.887 |
| Date | Value |
|---|---|
| October 02, 2026 | 9.035 |
| October 01, 2026 | 8.922 |
| September 30, 2026 | 8.612 |
| September 29, 2026 | 6.859 |
| September 28, 2026 | 7.061 |
| September 25, 2026 | 6.907 |
| September 24, 2026 | 7.048 |
| September 23, 2026 | 7.594 |
| September 22, 2026 | 8.471 |
| September 21, 2026 | 8.342 |
| September 18, 2026 | 8.073 |
| September 17, 2026 | 8.194 |
| September 16, 2026 | 8.284 |
| September 15, 2026 | 8.184 |
| September 14, 2026 | 8.178 |
| September 11, 2026 | 7.976 |
| September 10, 2026 | 7.971 |
| September 09, 2026 | 8.276 |
| September 08, 2026 | 8.471 |
| September 04, 2026 | 8.427 |
| September 03, 2026 | 8.437 |
| September 02, 2026 | 8.491 |
| September 01, 2026 | 8.196 |
| August 31, 2026 | 8.284 |
| August 28, 2026 | 8.014 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.436 |
| Alnylam Pharmaceuticals, Inc. | 5.821 |
| Anika Therapeutics, Inc. | 1.419 |
| Savara, Inc. | 7.120 |
| Vericel Corp. | 7.738 |
Price to Book Value Related Metrics
| PS Ratio | 154.76 |
| PEG Ratio | -0.0241 |
| Price | 29.43 |
| Earnings Yield | -34.12% |
| Market Cap | 1.864B |
| PEGY Ratio | -0.0241 |